26 | 2025 GIGA Annual Report EXTERNAL VALIDATION OF SERUM BIOMARKERS PREDICTING SHORT-TERM AND MID/LONG-TERM RELAPSE IN PATIENTS WITH CROHN’S DISEASE STOPPING INFLIXIMAB Pierre N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, Fléron M, Trzpiot L, Eppe G, De Pauw E, Laharie D, Satsangi J, Bossuyt P, Vuitton L, Vieujean S, Colombel JF, Meuwis MA, Louis E; GETAID and the SPARE-Biocycle research group. Researchers, including Nicolas Pierre from the Laboratory of Translational Gastroenterology, have confirmed distinct blood protein profiles predicting short-term and mid/long-term relapse in Crohn’s disease patients discontinuing anti-TNF-α therapy. This study validates findings from a previous cohort (STORI) using an independent patient group (SPARE), strengthening their potential to guide treatment decisions. By identifying early signs of disease reactivation, these biomarkers could help personalize therapy, reducing unnecessary risks and costs. Conducted through international collaboration, the research leveraged advanced proteomics technology to analyze blood samples from 300 patients, offering a precise and innovative approach to Crohn’s disease management. Gut. 2024 Nov 11;73(12):1965-1973. doi: 10.1136/gutjnl-2024-332648. p LINKS | News GIGA | Publication on ORBI | Nicolas Pierre
RkJQdWJsaXNoZXIy MTk1ODY=